Wang Xuan, Guo Jiaying, Dai Qiangfu
Department of Rheumatology and Immunology, The Second Affiliated Hospital of Wannan Medical College, Wuhu, China.
Department of Geriatric Medicine, The Second Affiliated Hospital of Wannan Medical College, Wuhu, China.
Front Cell Dev Biol. 2024 Oct 17;12:1492821. doi: 10.3389/fcell.2024.1492821. eCollection 2024.
Systemic sclerosis (SSc) is a complex autoimmune disease with clinical symptoms of vascular damage, immune disorders, and fibrosis, presenting significant treatment challenges and limited therapeutic options. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have been demonstrated in numerous studies as more effective than MSCs in treating autoimmune diseases. Recent studies demonstrate that MSC-EVs can significantly ameliorate the symptoms of SSc and mitigate pathological changes such as vascular injury, immune dysregulation, and fibrosis. These findings underscore the promising therapeutic potential of MSC-EVs in the treatment of SSc. MSC-EVs promote angiogenesis, modulate immune dysfunction, and combat fibrosis. This article summarizes the therapeutic applications and possible mechanisms of MSC-EVs for SSc, thereby offering a novel therapeutic direction for the treatment of SSc.
系统性硬化症（SSc）是一种复杂的自身免疫性疾病，具有血管损伤、免疫紊乱和纤维化等临床症状，带来了重大的治疗挑战且治疗选择有限。间充质干细胞衍生的细胞外囊泡（MSC-EVs）在众多研究中已被证明在治疗自身免疫性疾病方面比间充质干细胞更有效。最近的研究表明，MSC-EVs可以显著改善SSc的症状，并减轻诸如血管损伤、免疫失调和纤维化等病理变化。这些发现强调了MSC-EVs在治疗SSc方面具有广阔的治疗潜力。MSC-EVs促进血管生成、调节免疫功能障碍并对抗纤维化。本文总结了MSC-EVs在SSc治疗中的应用及可能机制，从而为SSc的治疗提供了一个新的治疗方向。
